Download to read the full chapter text
Chapter PDF
Literatur
Stefan H, Snead OC III (1997). Absence seizures. In: Engel J Jr, Peadley T (eds) Epilepsy. A comprehensive textbook. Lippincott Raven Publishers, Philadelphia, 579590.
Literatur
Commission on Classification and Terminology of the International League against Epilepsy (1989). Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389–399.
Literatur
Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992; 327:1769–73.
Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer surface protein lipoprotein A with adjuvant. N Engl J Med 1998;339:209–15.
Strie F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr 1999; 111: 911–915
Literatur
Harding A.E (1982). The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the Drew family of Walworth’. Brain, 105(Pt 1):1–28.
Klockgether T, Bürk T and Dichgans J (1996). Zerebelläre Bewegungsstörungen (Ataxien). In: Conrad B und Ceballos-Baumann A.O. (Hrsg.) Bewegungsstörungen in der Neurologie, Thieme, Stuttgart New York 254–279.
Tan E.-K. and Ashizawa T (2001). Genetic testing in spinocerebellar ataxias. Arch Neurol 58: 191–195.
Literatur
Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.
Literatur
Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.
Literatur
Moser HW (1997) Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120:1485–1508.
Singh I et al. (1998) Lovastatin for X-linked adrenoleukodystrophy. NEJM 339:702–703.
Literatur
Curran HV et al. (1994) Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agarophobia with panic disorder. Psychol Med 24:969–976.
Mavissakalian MR and Ryan MT (1998) Rational Treatment of Panic Disorder with Antidepressants. Ann Clin Psych 10:185–195.
Van Balkom A et al. (1997) A Meta-Analysis of the Treatment of Panic Disorders with or without Agoraphobia: A Comparison of Psychopharmacological, Cognitive-Behavioral and Combination Treatment. J Neur Ment Dis 185:510–516.
Literatur
Baxter PS et al. (1995) Vigabatrin monotherapy in resistant neonatal seizures. Seizure 4(1):57–9.
Talens C et al. (1987) Early stimulation: psychomotor development of two girls with Aicardi syndrome. Child Care Health Dev 13(2):101–9.
Literatur
Feasby TE, Gilbert JJ, Brown WF, et al. (1986) An acute axonal form of Guillain-Barré polyneuropathy. Brain 109:1115–1126.
Flachenecker P, Reiners K (1999). Twenty-fourhour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barre syndrome. J Neurol Sciences 165:144–153.
Flachenecker P, Toyka KV, Reiners K (2001). Herzrhythmusstörungen beim Guillain-Barre-Syndrom. Nervenarzt 72:610–617.
Hadden RDM, Cornblath DR, Hughes RAC, et al. (1998) The Plasma exchange/Sandoglobin Guillain-Barre Syndrome Trial Group. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol 44:780–788.
Hartung HP, Willison HJ, Kieseier BC (2002). Acute immunoinflammatory neuropathy: update on Guillain-Barre syndrome. Curr Opin Neurol 15 (5):571–577.
Hughes RAC, Swan AV, Cornblath DR, et al. (1997) Randomised trials of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 349:225–230.
Rees JH, Soudain SE, Gregson NA, Hughes RAC (1995). Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 23:1374–1379.
The Dutch Guillain-Barré Study Group (1994). Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Ann Neurol 35:749–752.
The Guillain-Barré Study Group (1985). Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35:1096–1104.
van der Meche FG, Schmitz PI and the Dutch Guillain-Barré Study Group (1992). A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barrésyndrome. N Engl J Med 326:1123–1129.
Literatur
Flachenecker P, Reiners K (1999). Twenty-fourhour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barre syndrome. J Neurol Sciences,165:144–153.
Flachenecker P, Toyka KV, Reiners K (2001). Herzrhythmusstörungen beim Guillain-Barre-Syndrom. Nervenarzt 72:610–617.
Flachenecker P, Wermuth P, Hartung H-P, Reiners K (1997). Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol 42:171–179.
Hilz MJ, Claus D, Bauer J, Neundörfer B (1990). Transcutaneous cardiac pacemaker for prevention and emergency therapy in neurologic intensive care patients. Nervenarzt 61(12):744–748.
Pfeiffer G, Schiller B, Kruse J, Netzer J (1999). Indicators of dysautonomia in severe Guillain Barre syndrome. J Neurol. 246:1015–1022.
Winer JB, Hughes RAC (1988). Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. Q J Med 257:735–739.
Literatur
Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A (2000). Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults (Cochrane Review). The Cochrane Library, Issue 2, Oxford Update Software.
Rutherford GW, Feldman KA, Kennedy, GE (2000). Three-or four-versus two-drug antiretroviral maintenance regimens for HIV infection (Cochrane Review). The Cochrane Library, Issue 2, Oxford Update Software.
Literatur
Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.
IONDT-group (ischemic optic neuropathy decompression trial search group) (1995) Optic nerve decompression surgery for NAION is not effective and may be harmful. JAMA 273: 625–632.
Literatur
Lumenta CB, Brückmann H, Feldmann HJ, Strupp ML, Wowra B (2001). Neurinome. In: Tumorzentrum München (Hrsg.) Hirntumoren und primäre Tumoren des Rückenmarks. Empfehlungen zur Diagnostik, Therapie und Nachsorge. Zuckschwerdt, München Bern Wien New York.
Literatur
Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.
Literatur
Bou J, Domenech T, Puig J et al. (2000) Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 410:33–41
Bou J, Domenech T, Gras J et al. (1997) Pharmacological profile of almotriptan, a novel antimigraine drug. Cephalalgia 17:421–422
Gras J, Bou J, Llenas J et al. (2000) Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 410:43–51
Fernandez FJ, Cabarrocas X, Zayas JM et al. for and on behalf of the Almotriptan Dose Finding Study Group (1999) Oral almotriptan in the treatment of migraine. Cephalalgia 19:362–362
Pascual J (2000) Therapy with other triptans: almotriptan. In: Diener HC (Hrsg.) Drug treatment of migraine and other headaches. Karger, Basel, S. 197–205
Pascual J, Falk RM, Piessens F et al. (2000) Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, doubleblind, placebo-controlled study. Cephalalgia 20:588–596
Cabarrocas X, Zayas JM, on behalf of the almotriptan Oral Study Group (1998) Efficacy data on oral almotriptan, a novel 5-HT1B/D agonist. Headache 38:377–378
Cabarrocas X, Zayas JM, for and on behalf of the Almotriptan Comparative Study Group (1999) Advantageous tolerability of almotriptan 12,5 mg compared with sumatriptan 100 mg. Headache 39:347
Martinez E, Cabarrocas X, Peris F et al. (1999) Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine. Cephalalgia 19:362
Pascual J, Falk RM, Docekal P et al. (2001) The tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 45 (4)
Almirall Prodesfarma, Bayer Vital GmbH 12,5 mg Filmtablette (2000) Fachinformation November 2000
Matthew NT (2000) Results of a 1-year open study on almotriptan. London, Headache World (abstract)
Literatur
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V for the Amyotrophic Lateral Sclerosis / Riluzole Study Group-II (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431.
Literatur
Aisen et al. (2000) A randomized trial of prednisone in Alzheimer’s disease. Neurology 54(3): 588–593.
Alastair J.J., Wood M.D (1999). Treatment of Alzheimer’s Disease. The New England Journal of Medicine 341:1670–1679.
Henderson et al. (2000) Estrogen for Alzheimer’s disease in women. Randomized, double-blind, placebo-controlled trial. Neurology 54:295–301.
In’t Veld BA, Ruitenberg A, Stricker BH et al. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345:1515–1521.
Knapp MJ, Knopmann DS, Soloman PR, Pendlebury WW, Davis CS, Gracon SI. A (1994). 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’disease. JAMA 271:985–991.
Le Bars PL, Katz MM, Berman N, Itil TM, Freedmann AM, Schatzberg AF (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginko biloba for dementia. JAMA 278:1327–1332.
Raskind MA, Peskind ER, Wessel T, Yuan W (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group Neurology. Jun 27; 54(12):2261–8.
Rösler M, Anand R, Cicin-Sain A, et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’disease: international randomized controlled trial. BMJ 318:633–638.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998). Donepezil study group. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimers’ disease. Neurology 50:136–145.
Sano M, Ernesto C, Thomas RG et al. (1997) A controlled trial of selegeline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336:1216–1222.
Literatur
Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.
Literatur
Kain Z et al. (2000) Midazolam: effects on amnesia and anxiety in children. Anesthesiology 93:676–84.
Verwey B et al. (2000) Memory impairment in those who attempted suicide by benzodiazepine overdose. J Clin Psychiatry 61:456–9.
Literatur
Mrazek M et al. (1999) Therapeutische Erfahrungen beim alkoholbedingten Korsakow-Syndrom. Nervenarzt 70:790–794.
Literatur
Rösler A et al. (1999) Precipitating factors of transient global amnesia. J Neurol 246:53–54.).
Berlit P (2000) Successful prophylaxis of recurrent transient global amnesia with metoprolol. Neurology 55:1937–1938.
Zeman AZJ & Hodges JR (1997). Transient global amnesia. Br J Hosp Med 58:257–260.
Literatur
Zeman AZ, Boniface SJ, Hodges JR (1998). Transient epileptic amnesia: A description of the clinical and neuropsychological features in 10 cases and a review of the literature. J Neurol Neurosurg Psychiatry 4:435–443.
Literatur
Gillmore JD, Davies J, Iqbal A, Madhoo S, Russell NH, Hawkins PN (1998) Allogenic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 100: 226–228.
Kyle RA, Dyck PJ (1993) Amyloidosis and neuropathy. In: Dyck PJ, Thomas PK (Hrsg) Peripheral neuropathy. WB Saunders Company, Philadelphia, pp 1294–1309.
Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336: 1202–1207.
Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation Amyloidose, in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101:766–769.
Literatur
ISUIA Investigators (1998) Unruptured intracranial aneurysms — risk of rupture and risks of surgical intervention. The New England Journal of Medicine 24:1725–1733.
Brilstra et al. (1999) Treatment of intracranial aneurysms by embolization with coil: a systematic review. Stroke 30(2):470–476.
Bederson et al. (2000) Recommendations for the management of patients with unruptured intracranial aneurysma. Stroke 31:2742–2750.
Literatur
Brilstra et al. (1999) Treatment of intracranial aneurysms by embolization with coil: a systematic review. Stroke 30(2):470–476. International Subarachnoid Aneurysm Trial (ISAT)
ISAT (International Subarachnoid Aneurysm Trial) Lancet 2002; 360:1267–1274
Literatur
Commission on Classification and Terminology of the International League against Epilepsy (1981). Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501.
Literatur
Commission on Classification and Terminology of the International League against Epilepsy (1981). Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501.
Literatur
Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO (2000). Infusion of alpha-galactosidase A reduces tissue globotriao-sylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365–370.
Abe A, Arend LJ, Lee L, Lingwood C, Brady RO, Shayman JA (2000). Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. Kidney Int 57:446–454.
Literatur
Krämer, G (1999). Epilepsien im höheren Lebensalter. Thieme, Stuttgart, New York.
Stefan H (1999). Epilepsien: Diagnose und Behandlung. Thieme, Stuttgart, New York.
Literatur
Tunick PA et al. (2002) Am J Cardiol 90:1320–25.
Literatur
Penkert G, Carvalho GA, Nikkhah G, Tatagiba M, Matthies C, Samii M (1999) Diagnosis and surgery of brachial plexus injuries. J Reconstr Microsurg 15: 3–8.
Literatur
Berlit P (1992) Clinical and laboratory findings with giant cell arteriitis. J Neurol Sci III, 1–12
Literatur
Kleihues P, Cavenee W (Hrsg.) (2000). Tumors of the Nervous System. WHO Classification of Tumours. IARC Press, Lyon.
Schlegel U, Westpahl M (Hrsg.) (1998). Neuroonkologie. Thieme, Stuttgart New York.
Walker MD, Green SB, Byar DP et al. (1980) Randomized comparisons of radiotherapy and nitrosureas for the treatment of malinant gliomas after surgery. New Engl J Med 303:1323–1329.
Shaw EG, Scheithauer BW, O’Fallon JR (1997). Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 31:273–278.
Peraud A, Kreth FW, Siefert A et al. (2001) Niedermaligne Gliome. In: Tumorzentrum München (Hrsg.) Hirntumoren und primäre Tumoren des Rückenmarks. Empfehlungen zur Diagnostik, Therapie und Nachsorge. Zuckschwerdt, München Bern Wien New York.
Albert FK, Forsting M, Sartor K et al. (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45–60.
Levin VA, Silver P, Hannigan J et al. (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Rad Oncol Biol Phys 18:321–324.
Hildebrandt J, Sahmoud T, Mignolet F et al. (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44:1479–1483.
Thomas DGT, Bleehan NM, Roberts JT et al. (1998) MRC randomised trial of adjuvant chemotherapy in high grade glioma (HGG)-BR05. J Neuro Oncol 39:102.
Yung WK, Prados MD, Yaya-Tur R et al. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762–71.
Literatur
Klockgether T, Bürck T, Dichgans J (1996). Zerebelläre Bewegungsstörungen (Ataxien). In: Conrad B und Ceballos-Baumann A.O. (Hrsg.) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York 254–279.
Tan E.-K. and Ashizawa T (2001). Genetic testing in spinocerebellar ataxias. Arch Neurol 58:191–195.
Literatur
Klockgether T, Bürk T und Dichgans J (1996). Zerebelläre Bewegungsstörungen (Ataxien). In: Conrad B and Ceballos-Baumann AO (Hrsg.) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York 254–279.
Tan EK and Ashizawa T (2001). Genetic testing in spinocerebellar ataxias. Arch Neurol 58: 191–195.
Literatur
Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.
Literatur
Confavreux C, Saddier P, Grimaud J. et al. (1996) Risk of cancer from azathioprine therapy in multiple sclerosis. A. case-control study. Neurology 46:1607–1612.
MS-Therapie Konsensus Gruppe (MSTKG), (1999). Immunmodulatorische Stufentherapie der Multiplen Sklerose. Nervenarzt 70:371–386.
MS-Therapie Konsensus Gruppe (MSTKG), (2001). Immunmodulatorische Stufentherapie der Multiplen Sklerose. I. Ergänzung Dezember 2000. Nervenarzt 72:150–157.
Pette M (1999). Immunsuppressive, immunmodulatorische Therapie. In: Zettl UK, Mix E (Hrsg.) Klinische Neuroimmunlogie, Verlag de Gruyter, Berlin-New York. S. 261–276.
Tolkoff-Rubin NE, Rubin RH (1996). The purin antagonists: Azathioprine and mycophenolat mofetil. In: KF Austen, SJ Burakoff, FS Rosen et al. (Hrsg.) Therapeutic Immunology. Blachwell sciences, Cambridge. S. 44–56.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2005). A. In: Berlit, P. (eds) Therapielexikon Neurologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26367-5_1
Download citation
DOI: https://doi.org/10.1007/3-540-26367-5_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67137-4
Online ISBN: 978-3-540-26367-8
eBook Packages: Medicine (German Language)